Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.9K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative MRI Uncovers Subtle Cortical Damage in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Annals of clinical and translational neurology·2026
Same author

Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

Myasthenia gravis misdiagnosis in the era of innovative therapies: Uncovering pitfalls and patterns.

Journal of neuroimmunology·2026
Same author

An automated quantitative report for multiple sclerosis using only 3D T2-fluid-attenuated inversion recovery MRI.

Neuroradiology·2026
Same author

The 2024 McDonald criteria for the diagnosis of multiple sclerosis: implications for clinical practice.

Practical neurology·2026

Related Experiment Video

Updated: Jan 25, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.3K

Myasthenia gravis.

Nils Erik Gilhus1,2, Socrates Tzartos3, Amelia Evoli4,5

  • 1Department of Clinical Medicine, University of Bergen, Bergen, Norway. nils.gilhus@uib.no.

Nature Reviews. Disease Primers
|May 4, 2019
PubMed
Summary

Myasthenia gravis (MG) is an autoimmune disorder causing muscle weakness due to antibodies attacking the acetylcholine receptor. Treatment aims for remission through immunotherapy, symptom management, and physical training.

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.8K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.3K

Related Experiment Videos

Last Updated: Jan 25, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.3K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.8K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.3K

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis (MG) is an autoimmune condition characterized by antibodies targeting the acetylcholine receptor (AChR) or related proteins.
  • This immune attack occurs at the postsynaptic muscle membrane, leading to muscle weakness.

Purpose of the Study:

  • To provide a comprehensive overview of Myasthenia Gravis.
  • To outline diagnostic approaches and therapeutic strategies for MG patients.
  • To emphasize the importance of personalized treatment and patient management.

Main Methods:

  • Review of current understanding of MG pathophysiology.
  • Analysis of diagnostic criteria, including antibody testing and neurophysiological examination.
  • Summary of therapeutic options, including symptomatic treatment, immunotherapy, and supportive care.

Main Results:

  • Diagnosis is typically confirmed by antibody tests in patients with characteristic symptoms.
  • Antibody-negative cases require thorough clinical and neurophysiological evaluation.
  • Treatment strategies are tailored to MG subgroups, aiming for remission and improved quality of life.

Conclusions:

  • Effective management of MG involves a multi-faceted approach including immunotherapy, symptomatic relief, and potentially thymectomy.
  • Prompt treatment of exacerbations, especially those involving respiratory failure, is critical.
  • Encouraging active physical training and managing comorbidities are essential for long-term patient well-being.